Adil Javed is a Neurology physician affiliated with University of Chicago Medical Center. OpenAlex indexes 70 publications with 1,823 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
888-824-0200Registry record last updated 24 Oct 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TG Therapeutics, Inc.Program year202519 payments$17,884openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
51.3%Gabapentinoids15.1%Gabapentin82%Pregabalin18%Part D≥66 patientsBenzodiazepine6.5%Clonazepam32%Alprazolam30%Diazepam26%Lorazepam12%Part D<11 patients+ 15 more classes in this area
Musculoskeletal
17.9%gamma-Aminobutyric Acid-ergic Agonist11.9%Baclofen100%Part D≥77 patientsCentral alpha-2 Adrenergic Agonist4.7%Tizanidine Hcl100%Part D≥26 patients+ 2 more classes in this area
Cancer & immunology
15.2%Pyrimidine Synthesis Inhibitor4.7%Aubagio75%Teriflunomide25%Part D<11 patientsOther immunosuppressants2.9%Tecfidera44%Dimethyl Fumarate38%Vumerity18%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Chmura, MD, PhD
University of Chicago Medical Center
Elaine Worcester
University of Chicago Medical Center
Luca Vricella
University of Chicago Medical Center
Ahmet Atik, MD
University of Chicago Medical Center
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”